BioNTech’s Bold Pivot: From Pandemic Heroics to Pioneering Cancer Therapies
BioNTech transitions from COVID-19 vaccine success to focus on mRNA-based cancer therapies. Despite a decrease in profits, BioNTech's revenues outperformed market expectations in late 2024. Strategic focus on BNT327, a…